Liang Zhou1,2,3, Zuwei Li1,4,3, Xiang Pan1,3,5, Yulin Lai1,2,5, Jing Quan1,3,5, Liwen Zhao1,3,5, Jinling Xu1, Weijie Xu1, Xin Guan1, Hang Li1, Shangqi Yang1, Yaoting Gui3, Yongqing Lai1,3. 1. Department of Urology, Peking University Shenzhen Hospital Shenzhen 518036, Guangdong, China. 2. Department of Urology, Guangzhou Medical University Guangzhou 511436, Guangdong, China. 3. The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center Shenzhen 518036, Guangdong, China. 4. Department of Urology, Shantou University Medical College Shantou 515041, Guangdong, China. 5. Department of Urology, Anhui Medical University Hefei 230032, Anhui, China.
Abstract
BACKGROUND: RCC is a malignant tumor that originates from renal tubular epithelial cells, accounting for nearly 90% of renal malignancies and 3% of adult malignancies. It was reported that more than 30-40% of patients with early localized RCC still have recurrence and metastasis after receiving radical surgery. miRNAs are an endogenous non-coding small RNAs that play an important role in the regulation of tumor cell proliferation, differentiation and apoptosis. METHODS: In our study, RT-qPCR, CCK-8 assay, wound scratch assay, transwell assay and flow cytometry assay were designed to identify the expression and functions of miR-18a-5p in RCC. Moreover, we collected the survival data from The Cancer Genome Atlas to predict and clarify the prognostic functions of miR-18a-5p in RCC. The correlation between miR-18a-5p expression and clinicopathological variables or overall survival was analyzed by 42 formalin-fixed paraffin-embedded (FFPE) renal cancer samples. RESULTS: The expression of miR-18a-5p in RCC tissues and cell lines was elevated. Further researches suggested that upregulation of miR-18a-5p had a positive effect on RCC cell proliferation, migration, invasion and inhibition of apoptosis, while down-regulation of miR-18a-5p neutralized the effect. In addition, Data of TCGA and prognostic analysis of FFPE RCC samples revealed that high miR-18a-5p expression patients had significantly poorer survival. CONCLUSIONS: These results demonstrated that miR-18a-5p functioned as an oncogene and prognostic biomarker in RCC.
BACKGROUND:RCC is a malignant tumor that originates from renal tubular epithelial cells, accounting for nearly 90% of renal malignancies and 3% of adult malignancies. It was reported that more than 30-40% of patients with early localized RCC still have recurrence and metastasis after receiving radical surgery. miRNAs are an endogenous non-coding small RNAs that play an important role in the regulation of tumor cell proliferation, differentiation and apoptosis. METHODS: In our study, RT-qPCR, CCK-8 assay, wound scratch assay, transwell assay and flow cytometry assay were designed to identify the expression and functions of miR-18a-5p in RCC. Moreover, we collected the survival data from The Cancer Genome Atlas to predict and clarify the prognostic functions of miR-18a-5p in RCC. The correlation between miR-18a-5p expression and clinicopathological variables or overall survival was analyzed by 42 formalin-fixed paraffin-embedded (FFPE) renal cancer samples. RESULTS: The expression of miR-18a-5p in RCC tissues and cell lines was elevated. Further researches suggested that upregulation of miR-18a-5p had a positive effect on RCC cell proliferation, migration, invasion and inhibition of apoptosis, while down-regulation of miR-18a-5p neutralized the effect. In addition, Data of TCGA and prognostic analysis of FFPE RCC samples revealed that high miR-18a-5p expression patients had significantly poorer survival. CONCLUSIONS: These results demonstrated that miR-18a-5p functioned as an oncogene and prognostic biomarker in RCC.
Authors: George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2004-02-18 Impact factor: 11.205
Authors: R Morimura; S Komatsu; D Ichikawa; H Takeshita; M Tsujiura; H Nagata; H Konishi; A Shiozaki; H Ikoma; K Okamoto; T Ochiai; H Taniguchi; E Otsuji Journal: Br J Cancer Date: 2011-11-01 Impact factor: 7.640
Authors: S Hirajima; S Komatsu; D Ichikawa; H Takeshita; H Konishi; A Shiozaki; R Morimura; M Tsujiura; H Nagata; T Kawaguchi; T Arita; T Kubota; H Fujiwara; K Okamoto; E Otsuji Journal: Br J Cancer Date: 2013-04-11 Impact factor: 7.640